Rebecca Taub
Director Madrigal Pharmaceuticals
Dr. Rebecca Taub is a pioneering biopharmaceutical executive and Chief Executive Officer of Madrigal Pharmaceuticals, where she leads the development of groundbreaking therapies for metabolic and fibrotic liver diseases. Under her leadership, Madrigal achieved a historic milestone with the first-ever FDA approval of resmetirom (Rezdiffra™) for nonalcoholic steatohepatitis (NASH), revolutionizing treatment for this progressive liver condition.
A physician-scientist and serial entrepreneur, Dr. Taub co-founded Madrigal in 2011 and has since steered the company from discovery to commercialization, leveraging her deep expertise in hepatology, metabolic disorders, and translational medicine. Previously, she held key roles at VIA Pharmaceuticals and Merck Research Laboratories, where she advanced programs in cardiovascular and liver diseases.
Trained in medicine and molecular biology, Dr. Taub’s early academic work uncovered foundational mechanisms of liver regeneration and metabolic regulation. Her unique blend of clinical insight, scientific acumen, and executive leadership has positioned her as a transformative figure in addressing unmet needs in fibrotic diseases.
Seminars
- Examining what the resmetirom clinical programme and post-approval experience have revealed about fibrosis regression, MASH resolution, and the characteristics of patients most likely to benefit
- Translating insights from serial biopsy, non-invasive testing, and longitudinal treatment response back into research to refine target validation, biomarker strategies, and preclinical models
- Understanding which elements of the development pathway could be applied across other fibrotic indications
- Exploring how emerging clinical and real-world data can guide lifecycle development, combination strategies, and the identification of additional patient populations where the underlying biology may be relevant
